JP2018121657A5 - - Google Patents

Download PDF

Info

Publication number
JP2018121657A5
JP2018121657A5 JP2018085040A JP2018085040A JP2018121657A5 JP 2018121657 A5 JP2018121657 A5 JP 2018121657A5 JP 2018085040 A JP2018085040 A JP 2018085040A JP 2018085040 A JP2018085040 A JP 2018085040A JP 2018121657 A5 JP2018121657 A5 JP 2018121657A5
Authority
JP
Japan
Prior art keywords
antibody according
heavy chain
light chain
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018085040A
Other languages
English (en)
Japanese (ja)
Other versions
JP6638018B2 (ja
JP2018121657A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018121657A publication Critical patent/JP2018121657A/ja
Publication of JP2018121657A5 publication Critical patent/JP2018121657A5/ja
Application granted granted Critical
Publication of JP6638018B2 publication Critical patent/JP6638018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018085040A 2011-06-02 2018-04-26 Fcレセプター結合タンパク質 Active JP6638018B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US61/492,617 2011-06-02
US201161498266P 2011-06-17 2011-06-17
US61/498,266 2011-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017037848A Division JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質

Publications (3)

Publication Number Publication Date
JP2018121657A JP2018121657A (ja) 2018-08-09
JP2018121657A5 true JP2018121657A5 (enExample) 2019-05-09
JP6638018B2 JP6638018B2 (ja) 2020-01-29

Family

ID=47259886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質

Country Status (14)

Country Link
US (6) US9359438B2 (enExample)
EP (2) EP2966089B1 (enExample)
JP (3) JP6104897B2 (enExample)
KR (1) KR102014554B1 (enExample)
CN (2) CN103619353B (enExample)
AU (2) AU2012262007B2 (enExample)
BR (1) BR112013030352B1 (enExample)
CA (1) CA2837527C (enExample)
ES (1) ES2748583T3 (enExample)
IL (1) IL229618B (enExample)
MX (1) MX343659B (enExample)
PH (1) PH12013502378A1 (enExample)
SG (2) SG195025A1 (enExample)
WO (1) WO2012167039A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009238605B2 (en) * 2008-04-25 2014-11-06 Biogen Idec Hemophilia Inc. Antibodies against FcRn and use thereof
SG195025A1 (en) 2011-06-02 2013-12-30 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015081073A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
KR101954906B1 (ko) 2014-04-30 2019-03-08 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역질환 치료용 조성물
PL3250610T3 (pl) * 2015-01-30 2024-01-29 Momenta Pharmaceuticals, Inc. Przeciwciała anty-FcRn i sposoby ich stosowania
EP3448429B1 (en) 2016-04-25 2021-01-13 Syntimmune Inc. Humanized affinity matured anti-fcrn antibodies
JP7094941B2 (ja) * 2016-07-29 2022-07-04 モメンタ ファーマシューティカルズ インコーポレイテッド Fcrn抗体及びその使用方法
KR20190089941A (ko) 2016-12-01 2019-07-31 사빅 글로벌 테크놀러지스 비.브이. 하이브리드 복합 뒷문
BR112019026694A2 (pt) * 2017-06-15 2020-06-23 UCB Biopharma SRL Método para o tratamento da trombocitopenia imune
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
AU2019307959B2 (en) * 2018-07-20 2025-09-25 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
IL299167A (en) 2020-06-17 2023-02-01 Univ Pennsylvania Compositions and methods for treating patients with gene therapy
EP4295154A1 (en) * 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
WO2022221236A1 (en) * 2021-04-14 2022-10-20 Genentech, Inc. In vitro cell-based assay for predicting pharmacokinetics and brain penetration of biologics
US20230212316A1 (en) * 2021-12-15 2023-07-06 Wisconsin Alumni Research Foundation IgG EPITOPE PEPTIDES THAT BIND RHEUMATOID FACTOR AND METHODS OF USE THEREOF
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2035317T5 (es) 1987-11-09 1998-03-16 Becton Dickinson Co Metodo para analizar celulas hematopoyeticas en una muestra.
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ATE529509T1 (de) 1997-01-21 2011-11-15 Gen Hospital Corp Selektion von proteinen unter verwendung von rna- protein-fusionen
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
DE60232672D1 (de) 2001-10-01 2009-07-30 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
ATE475431T1 (de) 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
EP1879920A2 (en) 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
AU2009238605B2 (en) 2008-04-25 2014-11-06 Biogen Idec Hemophilia Inc. Antibodies against FcRn and use thereof
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
JP5773650B2 (ja) * 2008-07-16 2015-09-02 株式会社医学生物学研究所 抗ヒトclcp1抗体とその用途
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
EP2409991B1 (en) * 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
SG195025A1 (en) 2011-06-02 2013-12-30 Dyax Corp Fc RECEPTOR BINDING PROTEINS
CN110785185B (zh) 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia

Similar Documents

Publication Publication Date Title
JP2018121657A5 (enExample)
AU2015287227B2 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP2014518883A5 (enExample)
JP2020536488A5 (enExample)
JP2015163068A5 (enExample)
JP2012501670A5 (enExample)
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JP2018510636A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2014111644A5 (enExample)
JP2017114866A5 (enExample)
JP2012116856A5 (enExample)
JP2017149720A5 (enExample)
WO2022135536A1 (zh) Cd3人源化抗体及其应用
JP2021502984A5 (enExample)
JP2019523221A5 (enExample)
JP2015525208A5 (enExample)
JP2013545455A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
CA2896548A1 (en) Multivalent binding protein compositions
RU2016100892A (ru) Антитела против tweakr и их применение
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2012501669A5 (enExample)
JP2014518615A5 (enExample)